Serum IL-10 and IL-12 levels reflect the response to chemotherapy but are influenced by G-CSF therapy and sepsis in children with soft tissue sarcomas

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 67, Issue , 2013, Pages 517-528

  Bien, Ewa ^a   Krawczyk, Malgorzata ^a   Izycka Swieszewska, Ewa ^a   Trzonkowski, Piotr ^a   Kazanowska, Bernarda ^b   Adamkiewicz Drozynska, Elzbieta ^a   Balcerska, Anna ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF WROC AW   (Poland)

Author keywords

Children; Interleukin 10; Interleukin 12; Monitoring; Response to therapy; Soft tissue sarcomas; Th1 Th2 balance

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; TUMOR MARKER;

ADOLESCENT; ARTICLE; BLOOD; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PRESCHOOL CHILD; PROGNOSIS; RECURRENT DISEASE; SARCOMA; SEPSIS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-10; INTERLEUKIN-12; MALE; PROGNOSIS; RECURRENCE; SARCOMA; SEPSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883862578     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.1051646     Document Type: Article

References (74)

1. Agarwal A., Agrawal U., Verma S., Mohanty N. K., Saxena S.: Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy. Immunopharmacol. Immunotoxicol., 2010;32:348-356
2. Arpinati M., Green C. L., Heimfeld S., Heuser J. E., Anasetti C.: Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood, 2000:95:2484-2490
3. Bastiaannet E., Groen H., Jager P. L., Cobben D. C., van der Graaf W. T., Vaalburg W., Hoekstra H. J.: The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat. Rev., 2004;30:83-101
4. Bermudes-Morales V. H., Peralta-Zaragoza O., Alcocer-Gonzalez J. M., Moreno J., Madrid-Marina V.: IL-10 expression is regulated by HPV E2 protein in cervical cancer cells. Mol. Med. Report., 2011;4:369-375
5. Bien E., Balcerska A., Adamkiewicz-Drożyńska E., Rapala M., Krawczyk M., Stepinski J.: Pre-treatment serum levels of interleukin-10, interleukin-12 and their ratio predict response to therapy and probability of event-free and overall survival in childhood soft tissue sarcomas, Hodgkin's lymphomas and acute lymphoblastic leukemias. Clin. Biochem., 2009;42:1144-1157
6. Bien E., Balcerska A., Niedzwiecki M., Krawczyk M., Rapala M., Trzonkowski P., Stepinski J.: G-CSF therapy and catheter-related Gram-positive sepsis increase serum IL-2 receptor α level and may falsely suggest a relapse in children with soft tissue sarcomas unless serum beta2-microglobulin, lactate dehydrogenase and C-reactive protein levels are determined concomitantly. Cytokine, 2011;55:347-352
7. Bien E., Kazanowska B., Dantonello T., Adamkiewicz-Drozynska E., Balcerska A., Madziara W., Rybczynska A., Nurzynska-Flak J., Solarz E., Kurylak A., Zalewska-Szewczyk B., Krawczyk M., Izycka-Swieszewska E., Rapala M., Koscielniak E.: Factors predicting survival in childhood malignant and intermediate vascular tumors: retrospective analysis of the Polish and German cooperative paediatric soft tissue sarcoma study groups and review of the literature. Ann. Surg. Oncol., 2010;17:1878-1889
8. Bien E., Krawczyk M., Izycka-Swieszewska E., Trzonkowski P., Kazanowska B., Adamkiewicz-Drozynska E., Balcerska A.: Deregulated systemic IL-10/IL-12 balance in advanced and poor prognosis paediatric soft tissue sarcomas. Biomarkers, 2013;18:204-215
9. Bonanno G., Procoli A., Mariotti A., Corallo M., Perillo A., Danese S., De Cristofaro R., Scambia G., Rutella S.: Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies. J. Transl. Med., 2010;8:114
10. Boneberg E. M., Hareng L., Gantner F., Wendel A., Hartung T.: Human monocytes express functional receptors for granulocyte colony-stimulating factor that mediate suppression of monokines and interferon-γ. Blood, 2000;95:270-276
11. Boneberg E. M., Hartung T.: Granulocyte colony-stimulating factor attenuates LPS-stimulated IL-1beta release via suppressed processing of proIL-1beta, whereas TNF-alpha release is inhibited on the level of proTNF-alpha formation. Eur. J. Immunol., 2002;32:1717-1725
12. Boomsma M. F., Grassen B., Slot E., Berbee M., Berkhof J., Meezenbroek Ede J., Slieker W., Visser A., Meijer S., Beelen R. H.: Breast cancer surgery-induced immunomodulation. J. Surg. Oncol., 2010;102:640-648
13. Charest M., Hickeson M., Lisbona R., Novales-Diaz J. A., Derbekyan V., Turcotte R. E.: FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur. J. Nucl. Med. Mol. Imaging, 2009;36:1944-1951
14. Cooper K. L., Madan J., Whyte S., Stevenson M. D., Akehurst R. L.: Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC. Cancer, 2011;11:404
15. Flamant F., Rodary C., Rey A., Praquin M. T., Sommelet D., Quintana E., Theobald S., Brunat-Mentigny M., Otten J., Voute P. A., Habrand J. L., Martelli H., Barrett A., Terrier-Lacombe M. J., Oberlin O.: Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. Eur. J. Cancer., 1998;34:1050-1062
16. Galizia G., Orditura M., Romano C., Lieto E., Castellano P., Pelosio L., Imperatore V., Catalano G., Pignatelli C., De Vita F.: Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin. Immunol., 2002;102:169-178
17. Garcia-Hernandez M. L., Hemandez-Pando R., Gariglio P., Berumen J.: Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumor and vascular cell proliferation. Immunology, 2002;105:231-243
18. Gianotti L., Fortis C., Braga M., Gentilini O., Vignali A., Di Carlo V.: Radical oncologic surgery affects the circulatory levels of interleukin 10. J. Surg. Oncol., 1997;66:244-247
19. Göebel A., Kavanagh E., Lyons A., Saporoschetz I. B., Soberg C., Lederer J. A., Mannick J. A., Rodrick M. L.: Injury induces deficient interleukin-12 production, but interleukin-12 therapy after injury restores resistance to infection. Ann. Surg., 2000;231:253-261
20. Gortzak E., Azzarelli A., Buesa J., Bramwell V. H., van Coevorden F., van Geel A. N., Ezzat A., Santoro A., Oosterhuis J. W., van Glabbeke M., Kirkpatrick A., Verweij J., E. O. R. T. C. Soft Tissue Bone Sarcoma Group and National Cancer Institute of Canada Clinical Trials Group/Canadian Sarcoma Group: A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur. J. Cancer, 2001;37:1096-1103
21. Hakim H., Flynn P. M., Knapp K. M., Srivastava D. K., Gaur A. H.: Etiology and clinical course of febrile neutropenia in children with cancer. J. Pediatr. Hematol. Oncol., 2009;31:623-629
22. Hamza T., Barnett J. B., Li B.: Interleukin 12 a key immunoregulatory cytokine in infection applications. Int. J. Mol. Sci., 2010;11:789-806
23. Hartung T., Doecke W. D., Bundschuh D., Foote M. A., Gantner F., Hermann C., Lenz A., Milwee S., Rich B., Simon B., Volk H. D., von Aulock S., Wendel A.: Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions. Clin. Pharmacol. Ther., 1999;66:415-424
24. Hazelzet J. A., Kornelisse R. F., van der Pouw Kraan T. C., Joosten K. F., van der Voort E., van Mierlo G., Suur M. H., Hop W. C., de Groot R., Hack C. E.: Interleukin 12 levels during the initial phase of septic shock with purpura in children: relation to severity of disease. Cytokine, 1997;9:711-716
25. Hsia C. Y., Huo T. I., Chiang S. Y., Lu M. F., Sun C. L., Wu J. C., Lee P. C., Chi C. W., Lui W. Y., Lee S. D.: Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur. J. Surg. Oncol., 2007;33:208-212
26. Hsiao S. H., Lee M. S., Lin H. Y., Su Y. C., Ho H. C., Hwang J. H., Lee C. C., Hung S. K.: Clinical significance of measuring levels of tumor necrosis factor-alpha and soluble interleukin-2 receptor in nasopharyngeal carcinoma. Acta Otolaryngol., 2009;129:1519-1523
27. Ishikawa M., Nishioka M., Hanaki N., Miyauchi T., Kashiwagi Y., Ioki H., Kagawa A., Nakamura Y.: Perioperative immune responses in cancer patients undergoing digestive surgeries. World. J. Surg. Oncol., 2009;7:7
28. Itakura E., Huang R. R., Wen D. R., Paul E., Wunsch P. H., Cochran A. J.: IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod. Pathol., 2011;24:801-809
29. Kallio R., Surcel H. M., Bloigu A., Syrjala H.: Balance between interleukin-10 and interleukin-12 in adult cancer patients with or without infections. Eur. J. Cancer, 2001;37:857-861
30. Karavasilis V., Seddon B. M., Ashley S., Al-Muderis O., Fischer C., Judson I.: Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer, 2008;112:1585-1591
31. Koscielniak E., Jurgens H., Winkler K., Burger D., Herbst M., Keim M., Bernhard G., Treuner J.: Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma study. Cancer, 1992;70:2557-2567
32. Koziol-Montewka M., Magrys A., Paluch-Oles J., Bogut A., Buczynski K., Jablonka S.: MPO and cytokines in the serum of cancer patients in the context of Candida colonization and infection. Immunol. Invest., 2006;35:167-179
33. Lauerova L., Dusek L., Simickova M., Kocak I., Vagundova M., Zaloudik J., Kovarik J.: Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma, 2002;49:159-166
34. Lissoni P., Fumagalli E., Malugani F., Ardizzoia A., Bucovec R., Tancini G., Gardani G. S.: Stimulation of IL-12 secretion by GM-CSF in advanced cancer patients. J. Biol. Regul. Homeost. Agents, 2001;15:163-165
35. Little D. J., Ballo M. T., Zagars G. K., Pisters P. W., Patel S. R., El-Naggar A. K., Garden A. S., Benjamin R. S.: Adult rhabdomyosarcoma: outcome following multimodality treatment. Cancer, 2002;95:377-388
36. Mahipal A., Terai M., Berd D., Chervoneva I., Patel K., Mastrangelo M. J., Sato T.: Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer. Immunol. Immunother., 2011;60:1039-1045
37. Marincola F. M., Jaffee E. M., Hicklin D. J., Ferrone S.: Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol., 2000;74:181-273
38. Martin J. G., Kurokawa C. S., Carpi M. F., Bonatto R. C., de Moraes M. A., Fioretto J. R.: Interleukin-12 in children with sepsis and septic shock. Rev. Bras. Ter. Intensiva., 2012;24:130-136
39. Mielcarek M., Graf L., Johnson G., Torok-Storb B.: Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation. Blood, 1998;92:215-222
40. Mocellin S., Marincola F. M., Young H. A.: Interleukin-10 and the immune response against cancer: a counterpoint. J. Leukoc. Biol., 2005;78:1043-1051
41. Mocellin S., Panelli M. C., Wang E., Nagorsen D., Marincola F. M.: The dual role of IL-10. Trends. Immunol., 2003;24:36-43
42. Monneret G., Finck M. E., Venet F., Debard A. L., Bohe J., Bienvenu J., Lepape A.: The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol. Lett., 2004;95:193-198
43. Novotny A. R., Emmanuel K., Ulm K., Bartels H., Siewert J. R., Weighardt H., Holzmann B.: Blood interleukin 12 as preoperative predictor of fatal postoperative sepsis after neoadjuvant radiochemotherapy. Br. J. Surg., 2006;93:1283-1289
44. Okamoto M., Ohe G., Oshikawa T., Nishikawa H., Furuichi S., Yoshida H., Sato M.: Induction of cytokines and killer cell activities by cisplatin and 5-fluorouracil in head and neck cancer patients. Anticancer Drugs, 2000;11:165-173
45. Protti M. P., De Monte L.: Cross-talk within the tumor microenvironment mediates Th2-type inflammation in pancreatic cancer. Oncoimmunology, 2012;1:89-91
46. Rabinovich A., Medina L., Piura B., Huleihel M.: Expression of IL-10 in human normal and cancerous ovarian tissues and cells. Eur. Cytokine. Netw., 2010;21:122-128
47. Ruka W., Rutkowski P., Kaminska J., Rysinska A., Steffen J.: Alterations of routine blond tests In adult patients with soft tissue sarcomas: relationships to cytokine serum levels and prognostic significance. Ann. Oncol., 2001;12:1423-1432
48. Rutkowski P., Kaminska J., Kowalska M., Ruka W., Steffen J.: Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis. Int. J. Cancer, 2002;100:463-471
49. Rutkowski P., Kaminska J., Kowalska M., Ruka W., Steffen J.: Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J. Surg. Oncol., 2003;84:151-159
50. Sakamoto T., Saito H., Tatebe S., Tsujitani S., Ozaki M., Ito H., Ikeguchi M.: Interleukin-10 expression significantly correlates with minor CD8+ T-cell infiltration and high microvessel density in patients with gastric cancer. Int. J. Cancer, 2006;118:1909-1914
51. Sato T., Terai M., Tamura Y., Alexeev V., Mastrangelo M. J., Selvan S. R.: Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol. Res., 2011;51:170-182
52. Sharma A., Khan R., Joshi S., Kumar L., Sharma M.: Dysregulation in T helper 1/T helper 2 cytokine ratios in patients with multiple myeloma. Leuk. Lymphoma, 2010;51:920-927
53. Sloand E. M., Kim S., Maciejewski J. P., Van Rhee F., Chaudhuri A., Barrett J., Young N. S.: Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood, 2000;95:2269-2274
54. Spellman J. E., Gollnick S. O., Zhang P. J., Tomasi T. B.: Cytokine production by human soft tissue sarcomas: implications for immunosuppression within the tumour bed. Surg. Oncol., 1996;5:237-244
55. Spunt S. L., Pappo A. S.: Childhood nonrhabdomyosarcoma soft tissue sarcomas are not adult-type tumors. J. Clin. Oncol., 2006;24:1958-1959
56. Spunt S. L., Skapek S. X., Coffin C. M.: Pediatric nonrhabdomyosarcoma soft tissue sarcomas. Oncologist, 2008;13:668-678
57. Stanilov N., Miteva L., Deliysky T., Jovchev J., Stanilova S.: Advanced colorectal cancer is associated with enhanced IL-23 and IL-10 serum levels. Lab. Med., 2010;41:159-163
58. Stanilova S. A., Karakolev Z. T., Dimov G. S., Dobreva Z. G., Miteva L. D., Slavov E. S., Stefanov C. S., Stanilov N. S.: High interleukin 12 and low interleukin 10 production after in vitro stimulation detected in sepsis survivors. Intensive. Care Med., 2005;31:401-407
59. Steinhauser M. L., Hogaboam C. M., Lukacs N. W., Strieter R. M., Kunkel S. L.: Multiple roles for IL-12 in a model of acute septic peritonitis. J. Immunol., 1999;162:5437-5443
60. Sultan I., Qaddoumi I., Yaser S., Rodriguez-Galindo C., Ferrari A.: Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2, 600 patients. J. Clin. Oncol., 2009;27:3391-3397
61. Sung L., Anderson J. R., Donaldson S. S., Spunt S. L., Crist W. M., Pappo A. S., Soft Tissue Sarcoma Committee of the Children's Oncology Group.: Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Eur. J. Cancer, 2004;40:1878-1885
62. Toubai T., Tanaka J., Ota S., Fukuhara T., Hashino S., Kondo T., Shono Y., Morioka M., Kawamura T., Masauzi N., Kakinoki Y., Kobayashi H., Kunieda Y., Kasai M., Kurosawa M. et al.: Effect of granulocyte colony-stimulating factor on IL-12 p40 production during chemotherapy for B-cell lineage non-Hodgkin's lymphoma patients. Eur. J. Haematol., 2006;77:403-409
63. Tsavaris N. B., Katsoulas H. L., Kosmas C., Papalambros E., Gouveris P., Papantoniou N., Rokana S., Kosmas N., Skopeliti M., Tsitsilonis O. E.: The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study. Oncology, 2004;67:403-410
64. Tsuboi K., Miyazaki T., Nakajima M., Fukai Y., Masuda N., Manda R., Fukuchi M., Kato H., Kuwano H.: Serum interleukin-12 and interleukin-18 levels as a tumour marker in patients with esophageal carcinoma. Cancer. Lett., 2004;205:207-214
65. von Aulock S., Boneberg E. M., Hartung T.: Intermittent G-CSF (filgrastim) treatment cannot induce lymphocytosis in volunteers. Clin. Pharmacol. Ther., 2000;68:104
66. Wakao D., Murohashi I., Tominaga K., Yoshida K., Kishimoto K., Yagasaki F., Itoh Y., Itoh K., Sakata T., Kawai N., Kayano H., Suzuki T., Matsuda A., Hirashima K., Bessho M.: Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma. Ann. Hematol., 2002;81:140-146
67. Wang G., Weng Y., Ishiguro Y., Sakamoto H., Morita S.: The effect of tramadol on serum cytokine response in patients undergoing pulmonary lobectomy. J. Clin. Anesth., 2005;17:444-450
68. Wang R., Lu M., Zhang J., Chen S., Luo X., Qin Y., Chen H.: Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer. J. Exp. Clin. Cancer. Res., 2011;30:62
69. Weighardt H., Heidecke C. D., Westerholt A., Emmanuilidis K., Maier S., Veit M., Gerauer K., Matevossian E., Ulm K., Siewert J. R., Holzmann B.: Impaired monocyte IL-12 production before surgery as a predictive factor for the lethal outcome of postoperative sepsis. Ann. Surg., 2002;235:560-567
70. Welte K., Gabrilove J., Bronchud M. H., Platzer E., Morstyn G.: Filgrastim (r-metHuG-CSF): the first 10 years. Blood, 1996;88:1907-1929
71. Wesolowski R., Budd G. T.: Use of chemotherapy for patients with bone and soft-tissue sarcomas. Cleve. Clin. J. Med., 2010;77:23-26
72. Wu H. P., Shih C. C., Lin C. Y., Hua C. C., Chuang D. Y.: Serial increase of IL-12 response and human leukocyte antigen-DR expression in severe sepsis survivors. Crit. Care, 2011;15:R224
73. Zakrzewska I., Poznanski J.: Serum levels of interleukin-10 in patients with ovarian carcinoma in response to chemotherapy. Przegl. Lek., 2003;60:18-20
74. Zisman D. A., Kunkel S. L., Strieter R. M., Gauldie J., Tsai W. C., Bramson J., Wilkowski J. M., Bucknell K. A., Standiford T. J.: Anti-interleukin-12 therapy protects mice in lethal endotoxemia but impairs bacterial clearance in murine Escherichia coli peritoneal sepsis. Shock, 1997;8:349-356